Delivery of Dissociated Islets Cells within Microporous Annealed Particle Scaffold to Treat Type 1 Diabetes.

Autor: Roosa CA; Department of Biomedical Engineering, University of Virginia, 415 Lane Rd, Charlottesville, Virginia 22903, USA., Ma M; Department of Surgery, University of Virginia, 1300 Jefferson Park Ave, Charlottesville, Virginia 22903, USA., Chhabra P; Department of Surgery, University of Virginia, 1300 Jefferson Park Ave, Charlottesville, Virginia 22903, USA., Brayman K; Department of Surgery, University of Virginia, 1300 Jefferson Park Ave, Charlottesville, Virginia 22903, USA., Griffin D; Department of Biomedical Engineering, University of Virginia, 415 Lane Rd, Charlottesville, Virginia 22903, USA.; Department of Chemical Engineering, University of Virginia, 351 McCormick Rd, Charlottesville, Virginia 22904, USA.
Jazyk: angličtina
Zdroj: Advanced therapeutics [Adv Ther (Weinh)] 2022 Sep; Vol. 5 (9). Date of Electronic Publication: 2022 Jul 02.
DOI: 10.1002/adtp.202200064
Abstrakt: Type 1 diabetes (T1D) is caused by the autoimmune loss of insulin-producing beta cells in the pancreas. The only clinical approach to patient management of blood glucose that doesn't require exogenous insulin is pancreas or islet transplantation. Unfortunately, donor islets are scarce and there is substantial islet loss immediately after transplantation due, in part, to the local inflammatory response. The delivery of stem cell-derived beta cells ( e.g., from induced pluripotent stem cells) and dissociated islet cells hold promise as a treatment for T1D; however, these cells typically require re-aggregation in vitro prior to implantation. Microporous scaffolds have shown high potential to serve as a vehicle for organization, survival, and function of insulin-producing cells. In this study, we investigated the use of microporous annealed particle (MAP) scaffold for delivery of enzymatically dissociated islet cells, a model beta cell source, within the scaffold's interconnected pores. We found that MAP-based cell delivery enables survival and function of dissociated islets cells both in vitro and in an in vivo mouse model of T1D.
Competing Interests: Competing Interests: Donald Griffin has financial interests in Tempo Therapeutics which aims to commercialize MAP technology for dermal wound healing.
Databáze: MEDLINE
Externí odkaz: